Labcorp Holdings Inc.
NYSE:LHMedical - Diagnostics & Research
-$3.46 today
- Market cap
- $30.11B
- Beta
- 0.88
- P/E (TTM)
- 22.4
- EPS (TTM)
- $11.44
- Dividend yield
- 1.12%
Volume 0.69M
Average 0.63M
LH Net Receivables
Amounts owed to the company by customers and others, net of allowances for uncollectible accounts.
Labcorp Holdings Inc.NYSE: LH
Net Receivables · Q2 FY2026 · quarter ended Jun 2026
Net receivables rises 10.0% from a year ago
Net receivables stood at $2.5B at the end of Q2 FY2026, up 10.0% from a year earlier and up 2.2% from the prior quarter. Over 3 fiscal years it compounded at +4.2% a year.
Context
- Net receivables amounted to 13.5% of total assets at the end of Q2 FY2026, up 0.9 pp from a year earlier.
- Net receivables increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether net receivables keeps rising in the next quarterly balance sheet after a +10.0% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Net Receivables history
USD · from the balance sheet
- Latest · FY2025
- 2.26B USD
- Year-over-year change
- +7.8%
- 4-year CAGR
- -6.7%
| Period | Period end | Net Receivables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 2.26B | +7.8% |
| FY2024 | 2024-12-31 | 2.1B | -0.1% |
| FY2023 | 2023-12-31 | 2.1B | +5.1% |
| FY2022 | 2022-12-31 | 2B | -32.9% |
| FY2021 | 2021-12-31 | 2.98B | — |
Net Receivables vs competitors
How LH compares with its peers on the latest reported figures
- LH's Jun 2026 net receivables of $2.5B is the 2nd highest of the 7 companies compared; the peer median is $410.51M.
- Its year-over-year change of +10.0% is the 5th highest of 7, against a peer median of +19.1%.
- Net receivables amounts to 13.5% of total assets for LH, versus a peer median of 9.2%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Sep 2026 | $9.63B | -8.6% | +3.9% | 8.4% | |
| Jun 2026 | $2.5B | +10.0% | +4.2% | 13.5% | |
| Sep 2026 | $1.71B | +17.6% | +5.6% | 9.9% | |
| Jun 2026 | $421.97M | +36.5% | +6.7% | 15.9% | |
| Jun 2026 | $399.05M | +3.4% | -2.5% | 6.8% | |
| Sep 2026 | $186.55M | +61.4% | +12.3% | 9.9% | |
| Jun 2026 | $19.76M | +20.6% | -0.6% | 0.7% | |
| Peer median (excluding LH) | $410.51M | +19.1% | +4.7% | 9.2% | |
Competitors are the stored peer set for LH. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 1.47B | 320.6M | 536.8M | 1.52B | 532.3M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 |
| Net Receivables | 2.98B | 2B | 2.1B | 2.1B | 2.26B |
| Inventory | 401.4M | 470.6M | 474.6M | 493.2M | 534.7M |
| Other Current Assets | 0 | 1.84B | 655.3M | 697.6M | 1 |
| Total Current Assets | 5.33B | 4.63B | 3.77B | 4.81B | 4.02B |
| Property, Plant & Equipment (Net) | 2.82B | 2.79B | 2.91B | 3.05B | 3.08B |
| Goodwill | 7.96B | 6.12B | 6.14B | 6.37B | 6.79B |
| Intangible Assets | 3.74B | 3.12B | 3.34B | 3.49B | 3.6B |
| Long-term Investments | 60.9M | 65.7M | 26.9M | 16.3M | 153.9M |
| Tax Assets | 21.6M | 6.4M | 0 | 0 | 0 |
| Other Non-current Assets | 462.6M | 3.42B | 536.5M | 652.2M | 751.3M |
| Total Non-current Assets | 15.05B | 15.53B | 12.96B | 13.57B | 14.37B |
| Total Assets | 20.39B | 20.16B | 16.73B | 18.38B | 18.39B |
| Account Payables | 621.3M | 852.2M | 827.5M | 875.8M | 840.8M |
| Short-term Debt | 1.5M | 301.3M | 999.8M | 1B | 695.8M |
| Tax Payables | 239.6M | 146.1M | 127.5M | 152.7M | 0 |
| Deferred Revenue | 558.5M | 310.6M | 421.7M | 392.2M | 439.1M |
| Other Current Liabilities | 735.5M | 1.1B | 431.4M | 495.4M | 847.8M |
| Total Current Liabilities | 2.78B | 3.08B | 3.23B | 3.33B | 2.82B |
| Long-term Debt | 5.42B | 5.04B | 4.05B | 5.33B | 5.77B |
| Deferred Tax Liabilities | 762.9M | 543.4M | 417.9M | 383.1M | 454.5M |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 402M | 642.4M | 409.3M | 517.4M | (34.8M) |
| Total Non-current Liabilities | 7.31B | 6.96B | 5.61B | 6.98B | 6.93B |
| Total Liabilities | 10.09B | 10.04B | 8.83B | 10.31B | 9.76B |
| Common Stock | 8.5M | 8.1M | 7.7M | 7.6M | 7.5M |
| Retained Earnings | 10.46B | 10.58B | 7.89B | 8.3B | 8.64B |
| Accumulated OCI | (192M) | (493.2M) | (59.3M) | (261.6M) | (27.6M) |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 20.6M | 18.9M | 15.5M | 14.3M | 16.9M |
| Total Equity | 10.29B | 10.12B | 7.89B | 8.07B | 8.64B |
| Total Debt | 6.34B | 6.25B | 5.95B | 7.27B | 7.2B |
| Net Debt | 4.87B | 5.93B | 5.42B | 5.75B | 6.67B |
Labcorp Holdings Inc.
NYSE:LH
Intrinsic Alpha fair value
Locked
Current Price
$370.78
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.